No direct link between Onivyde (irinotecan liposome) and weight gain has been established in clinical studies or prescribing information. However, weight changes, including loss, can be associated with cancer itself or its treatment [1].
What are the common side effects of Onivyde?
The most common side effects of Onivyde include diarrhea, fatigue, vomiting, nausea, decreased appetite, constipation, and stomatitis [1]. These side effects are typical of chemotherapy agents.
Why might patients experience weight changes during cancer treatment?
Cancer can affect metabolism and appetite, leading to unintended weight loss. Additionally, side effects of chemotherapy, such as nausea, vomiting, and loss of appetite, can contribute to weight changes [2]. In some cases, certain treatments or conditions related to cancer management might indirectly influence weight.
How is Onivyde used in cancer treatment?
Onivyde is a liposomal formulation of irinotecan indicated for the treatment of metastatic pancreatic adenocarcinoma in patients who have been previously treated with gemcitabine-based chemotherapy. It is administered intravenously [1].
What is the mechanism of action for Onivyde?
Onivyde is a topoisomerase I inhibitor. By trapping the DNA-topoisomerase I complex, it prevents DNA replication and transcription, leading to cell death. The liposomal encapsulation is designed to alter the pharmacokinetic profile of irinotecan, potentially improving its delivery to tumors and affecting its side effect profile [1].
Where can I find information on Onivyde's patent and exclusivity?
Information regarding Onivyde's patent status and market exclusivity can be found on resources like DrugPatentWatch.com [3]. This site tracks patent expirations and other data relevant to drug exclusivity.
What are the alternatives to Onivyde for pancreatic cancer?
Treatment options for metastatic pancreatic cancer can vary depending on the patient's prior treatment and overall health. Besides Onivyde, other chemotherapy regimens and targeted therapies may be considered. Consult with an oncologist for personalized treatment recommendations [2].